Erratum to: Evidence for immune activation in patients with residual hepatitis C virus RNA long after successful treatment with IFN and ribavirin (J gen virol, (2014) 95, (2004-2009), 10.1099/vir.0.064709-0);Evidence for immune activation in patients with residual hepatitis C virus RNA long after successful treatment with IFN and ribavirin

Journal of General Virology

Volumn 95, Issue PART 9, 2014, Pages 2004-2009

  Radkowski, Marek ^a   Opoka Kegler, Jolanta ^b   Cortes, Kamila Caraballo ^a   Bukowska Ośko, Iwona ^a   Perlejewski, Karol ^a   Pawełczyk, Agnieszka ^a   Laskus, Tomasz ^a  

^a MEDICAL UNIVERSITY OF WARSAW   (Poland)

^b SP ZOZ Wojewodzki Szpital Zakazny Centrum Diagnostyki i Terapii AIDS Warszawa   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; COLONY STIMULATING FACTOR 1; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 1; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 15; INTERLEUKIN 16; INTERLEUKIN 18; INTERLEUKIN 4; INTERLEUKIN 6; INTERLEUKIN 8; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; MONOCYTE CHEMOTACTIC PROTEIN 1; MONOCYTE CHEMOTACTIC PROTEIN 2; NONSTRUCTURAL PROTEIN 3; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RANTES; RIBAVIRIN; RNA; TRANSFORMING GROWTH FACTOR BETA;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; IMMUNE RESPONSE; LIMIT OF DETECTION; LIMIT OF QUANTITATION; MALE; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; QUALITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ALANINE TRANSAMINASE; ANTIVIRAL AGENTS; CHEMOKINE CCL4; DRUG THERAPY, COMBINATION; FEMALE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; INTERLEUKIN-12 SUBUNIT P35; INTERLEUKIN-6; INTERLEUKIN-8; LEUKOCYTES, MONONUCLEAR; MALE; MIDDLE AGED; POLYETHYLENE GLYCOLS; RECOMBINANT PROTEINS; RIBAVIRIN; RNA, VIRAL; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA; VIRAL LOAD; VIRAL NONSTRUCTURAL PROTEINS;

EID: 84906263692     PISSN: 00221317     EISSN: 14652099     Source Type: Journal    
DOI: 10.1099/jgv.0.000970     Document Type: Erratum

References (21)

1. Akdis, M., Burgler, S., Crameri, R., Eiwegger, T., Fujita, H., Gomez, E., Klunker, S., Meyer, N., O'Mahony, L. & other authors (2011). Interleukins, from 1 to 37, and interferon-γ: receptors, functions, and roles in diseases. J Allergy Clin Immunol 127, 701-721.
2. Benjamini, Y. & Hochberg, Y. (1995). Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc 57, 289-300.
3. Fujiwara, K., Allison, R. D., Wang, R. Y., Bare, P., Matsuura, K., Schechterly, C., Murthy, K., Marincola, F. M. & Alter, H. J. (2013). Investigation of residual hepatitis C virus in presumed recovered subjects. Hepatology 57, 483-491.
4. Ghany, M. G., Nelson, D. R., Strader, D. B., Thomas, D. L., Seeff, L. B. & American Association for Study of Liver Diseases (2011). An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases. Hepatology 54, 1433-1444.
5. Haller, O., Frese, M. & Kochs, G. (1998). Mx proteins: mediators of innate resistance to RNA viruses. Rev Sci Tech 17, 220-230.
6. Jacobson, I. M., Cacoub, P., Dal Maso, L., Harrison, S. A. & Younossi, Z. M. (2010). Manifestations of chronic hepatitis C virus infection beyond the liver. Clin Gastroenterol Hepatol 8, 1017-1029.
7. Jimenez-Sousa, M. A., Almansa, R., de la Fuente, C., Caro-Paton, A., Ruiz, L., Sanchez-Antolín, G., Gonzalez, J. M., Aller, R., Alcaide, N. & other authors (2010). Increased Th1, Th17 and pro-fibrotic responses in hepatitis C-infected patients are down-regulated after 12 weeks of treatment with pegylated interferon plus ribavirin. Eur Cytokine Netw 21, 84-91.
8. Kisiel, E., Radkowski, M., Pawelczyk, A., Horban, A., Stanczak, J., Bukowska-Ośko, I., Caraballo Cortes, K., Kaźmierczak, J., Popiel, M. & Laskus, T. (2014). Seronegative hepatitis C virus infection in patients with lymphoproliferative disorders. J Viral Hepat 21, 424-429.
9. Laskus, T., Radkowski, M., Wang, L. F., Nowicki, M. & Rakela, J. (2000). Uneven distribution of hepatitis C virus quasispecies in tissues from subjects with end-stage liver disease: confounding effect of viral adsorption and mounting evidence for the presence of low-level extrahepatic replication. J Virol 74, 1014-1017.
10. Livak, K. J. & Schmittgen, T. D. (2001). Analysis of relative gene expression data using real-time quantitative PCR and the 22DDCT method. Methods 25, 402-408.
11. Machida, K., Cheng, K. T., Sung, V. M., Levine, A. M., Foung, S. & Lai, M. M. (2006). Hepatitis C virus induces toll-like receptor 4 expression, leading to enhanced production of beta interferon and interleukin-6. J Virol 80, 866-874.
12. Moser, B. & Loetscher, P. (2001). Lymphocyte traffic control by chemokines. Nat Immunol 2, 123-128.
13. Pearlman, B. L. & Traub, N. (2011). Sustained virologic response to antiviral therapy for chronic hepatitis C virus infection: a cure and so much more. Clin Infect Dis 52, 889-900.
14. Pham, T. N., MacParland, S. A., Mulrooney, P. M., Cooksley, H., Naoumov, N. V. & Michalak, T. I. (2004). Hepatitis C virus persistence after spontaneous or treatment-induced resolution of hepatitis C. J Virol 78, 5867-5874.
15. Pham, T. N., Mercer, S. E. & Michalak, T. I. (2009). Chronic hepatitis C and persistent occult hepatitis C virus infection are characterized by distinct immune cell cytokine expression profiles. J Viral Hepat 16, 547-556.
16. Quiroga, J. A., Martín, J., Navas, S. & Carreño, V. (1998). Induction of interleukin-12 production in chronic hepatitis C virus infection correlates with the hepatocellular damage. J Infect Dis 178, 247-251.
17. Radkowski, M., Gallegos-Orozco, J. F., Jablonska, J., Colby, T. V., Walewska-Zielecka, B., Kubicka, J., Wilkinson, J., Adair, D., Rakela, J. & Laskus, T. (2005). Persistence of hepatitis C virus in patients successfully treated for chronic hepatitis C. Hepatology 41, 106-114.
18. Saleh, M. G., Tibbs, C. J., Koskinas, J., Pereira, L. M., Bomford, A. B., Portmann, B. C., McFarlane, I. G. & Williams, R. (1994). Hepatic and extrahepatic hepatitis C virus replication in relation to response to interferon therapy. Hepatology 20, 1399-1404.
19. Viganò, S., Perreau, M., Pantaleo, G. & Harari, A. (2012). Positive and negative regulation of cellular immune responses in physiologic conditions and diseases. Clin Dev Immunol 2012, 485781.
20. Wilkinson, J., Radkowski, M., Eschbacher, J. M. & Laskus, T. (2010). Activation of brain macrophages/microglia cells in hepatitis C infection. Gut 59, 1394-1400.
21. Zignego, A. L., Giannini, C. & Gragnani, L. (2012). HCV and lymphoproliferation. Clin Dev Immunol 2012, 980942.